US Food and Drug Administration approves Teva leukemia drug

By REUTERS
October 26, 2012 17:20

The US Food and Drug Administration on Friday said it has approved a new leukemia treatment from Israel-headquartered Teva Pharmaceutical Industries Ltd to be sold under the brand name Synribo.

The drug, also known as omacetaxine mepesuccinate, is approved to treat a type of the blood and bone marrow cancer called chronic myelogenous leukemia, or CML, in patients whose cancer has progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors."Today's approval provides a new treatment option for patients who are resistant to or cannot tolerate other FDA-approved drugs for chronic or accelerated phases of CML," Richard Pazdur, director of the Office of Hematology and Oncology Products in FDA's Center for Drug Evaluation and Research, said in a statement.


Related Content

Breaking news
September 19, 2019
Liberman: Netanyahu leads ‘Jewish law block,’ serves only himself

By JERUSALEM POST STAFF